Latest news with #Non-AlcoholicSteatohepatitis
Time of India
12-07-2025
- Health
- Time of India
Why fatty liver disease is increasing even among non-drinkers: Check early symptoms, risk factors
Fatty liver disease, also known as hepatic steatosis, occurs when excess fat builds up in the liver. While some amount of fat in the liver is considered normal, too much can interfere with liver function and lead to serious complications. The condition is classified into two major types—Alcoholic Fatty Liver Disease (ALD) and Non-Alcoholic Fatty Liver Disease (NAFLD)—depending on the cause of fat accumulation. Alcoholic vs Non-Alcoholic: Key Differences As per Healthline, Alcoholic Fatty Liver Disease is caused by excessive and prolonged alcohol consumption. When not addressed, it can progress to alcoholic hepatitis and eventually cirrhosis, both of which cause permanent liver damage. Symptoms may include abdominal discomfort, fatigue, jaundice, and in severe cases, fluid accumulation and confusion. In contrast, Non-Alcoholic Fatty Liver Disease is not linked to alcohol use. Instead, it is closely associated with metabolic issues like obesity, insulin resistance, and high cholesterol. NAFLD can also progress from a simple fatty liver to Non-Alcoholic Steatohepatitis (NASH), a more serious condition involving inflammation and liver cell damage, potentially leading to fibrosis, cirrhosis, or even liver cancer. by Taboola by Taboola Sponsored Links Sponsored Links Promoted Links Promoted Links You May Like The New Honda City Sport Honda Book Now Undo The Silent Nature of the Disease Both ALD and NAFLD are often asymptomatic in early stages. Many people remain unaware they have liver damage until it has progressed significantly. In NAFLD, early warning signs may include persistent fatigue, upper right abdominal discomfort, and unexplained weight loss. Blood tests might show elevated liver enzymes, indicating inflammation or injury. When the disease advances to cirrhosis, symptoms can become more visible—yellowing of the skin (jaundice), swelling in the abdomen or legs, easy bruising, and mental confusion. Modern Lifestyle and Liver Stress NAFLD has become more prevalent due to sedentary lifestyles, poor dietary choices, stress, and sleep deprivation. Consumption of processed foods, sugary drinks, and lack of physical activity are considered major contributors. Medical experts warn that NAFLD is becoming one of the leading causes of liver-related complications globally. The liver plays a crucial role in detoxifying the body, processing everything from alcohol to medications to fatty food. When it's overburdened, the impact is felt throughout the body in the form of fatigue, digestive issues, hormonal imbalances, and more. Risk Factors to Watch While ALD is primarily caused by alcohol, its severity can be influenced by malnutrition, age, and underlying viral hepatitis. On the other hand, NAFLD risk increases with: Obesity or excess abdominal fat Type 2 diabetes or insulin resistance High triglycerides or low HDL cholesterol Sleep apnea, hypothyroidism, and polycystic ovary syndrome Rapid weight loss or malnourishment Older individuals are particularly vulnerable to both forms. What Can Be Done? For ALD, the cornerstone of treatment is complete abstinence from alcohol. Improvement is often seen once alcohol consumption stops. NAFLD requires a multifaceted approach: Weight loss through healthy diet and exercise Better control of blood sugar and cholesterol Avoiding processed and sugary foods Improving sleep quality Increasing physical activity, such as 30 minutes of walking daily Even modest weight loss—around 5–10% of body weight—can significantly improve liver health . Fatty liver disease is no longer an issue limited to heavy drinkers. With changing lifestyles, more people—regardless of their alcohol intake—are at risk. While the liver is a silent worker, its deterioration can have widespread effects. Early detection and lifestyle changes are critical for preventing long-term damage and ensuring overall well-being.
New Indian Express
09-07-2025
- Health
- New Indian Express
NAFLD: Sober but still at risk
You may not feel it and there may be no symptoms at all. But deep inside your body, your liver could be quietly storing fat, even if you've never touched a drop of alcohol. That's the unnerving reality of non-alcoholic fatty liver disease (NAFLD), a condition that's crawling into more lives than ever, silently and steadily. What exactly do you mean by NAFLD? 'It is a condition where fat builds up in your liver, for reasons other than alcohol,' says Dr Narendra Teja Gogireddy, consultant surgical gastroenterologist at Apollo Hospitals, Hyderguda, further adding, 'This term is used for patients with chronic lifestyle diseases. In initial stages it is mild and reversible, however it can cause liver damage over time and lead to serious conditions like cirrhosis or liver failure.' The condition often stems from everyday habits that seem harmless at first; a sedentary routine, meals loaded with sugar and processed carbs, and that familiar struggle with weight gain. 'People who drink little or no alcohol may develop NAFLD. People who are overweight or obese frequently exhibit it. The most prevalent type of liver disease in the world today is NAFLD. Although NAFLD in its early stages is typically benign and asymptomatic, it can develop into more severe forms such as Non-Alcoholic Steatohepatitis (NASH), which involves damage and inflammation of the liver. NASH can result in cirrhosis, scarring (fibrosis), and potentially liver failure or malignancy if treatment is not received,' explains Dr Naveen Polavarapu, senior consultant, medical gastroenterologist, liver specialist, lead, advanced endoscopic interventions & training, clinical director, Yashoda Hospitals, Hyderabad. What's alarming is that NAFLD doesn't discriminate, 'Fat can build up in your liver even if you don't drink alcohol. This happens due to several factors like insulin resistance (often linked with type 2 diabetes or prediabetes), high cholesterol or triglyceride levels, poor diet (especially diets high in sugar and refined carbs), sedentary lifestyle (lack of physical activity), rapid weight loss or malnutrition, certain medications (like corticosteroids or some cancer drugs), hormonal imbalances or metabolic syndrome. These risk factors can lead to fat accumulation in liver cells, potentially causing inflammation, scarring, and liver damage over time if not managed,' says Dr Narendra.
Time of India
02-06-2025
- Health
- Time of India
PGI researchers give new hope for treatment of severe liver disease
Lucknow: Advanced scientific research conducted by scientists at Sanjay Gandhi Postgraduate Institute of Medical Sciences (SGPGIMS) has shown a new way to treat Non-Alcoholic Steatohepatitis (NASH) – a severe but common liver disease. Tired of too many ads? go ad free now The research, led by Rohit A Sinha, a scientist and associate professor in the endocrinology department, along with his team comprising Sana Raza and Pratima Gupta, proved that a naturally occurring hormone called dehydroepiandrosterone (DHEA) can help in checking liver damage caused by NASH by removing harmful fat from liver cells, reducing inflammation, and preventing liver damage. A Union health ministry document notes that NASH is the severest form of Non-Alcoholic Fatty Liver Disease (NAFLD). Terming it as "a silent epidemic", the document noted that NAFLD's community prevalence ranges from 9% to 32%, depending on age, gender, area of residence, and socioeconomic status. This means that up to three people out of 10 could have fatty liver or a related disease. What raises concerns is that 20% of people with NAFLD develop NASH. "DHEA is a parent hormone that acts as a precursor to sex hormones in humans. While scanning several case studies of NASH patients, we noted that the level of DHEA in them was on the lower side. Keeping this as the base, we proposed to study the impact of increasing this hormone in NASH patients with a significant extent of fibrosis – a symptom of NASH," said Sinha, adding that the study was published in the journal 'Molecular and Cellular Endocrinology'. "We began with animal studies. In the mouse model, we fed the experimental group with a NASH-inducing diet. When the condition was confirmed in them, we injected DHEA. The outcome showed that the severity of liver damage in 80% of the sample decreased by about 60%," he said. The results paved the way for a cellular study in which the researchers worked upon lab-grown human liver cells. "Here too, in the experimental group, we loaded the cells with excessive fat to create a NASH-like condition. Thereafter, we introduced DHEA and found that the fat percentage decreased by up to 80%," said Sinha. "The result has been heartening. We now look forward to clinical trials for hormone replacement therapy," he said.
Yahoo
13-05-2025
- Business
- Yahoo
Non-Alcoholic Steatohepatitis (NASH) Pipeline Insight Report, 2025 - Featuring Analysis of Inventiva Pharma, Cirius Therapeutics, Terns Pharmaceuticals, HighTide Biopharma, Eli Lilly and Company, and More
Dublin, May 13, 2025 (GLOBE NEWSWIRE) -- The "Non-Alcoholic Steatohepatitis (NASH) - Pipeline Insight, 2025" clinical trials has been added to report provides comprehensive insights about 80+ companies and 80+ pipeline drugs in Non-Alcoholic Steatohepatitis (NASH) pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this HighlightsThe companies and academics are working to assess challenges and seek opportunities that could influence Non-Alcoholic Steatohepatitis (NASH) R&D. The therapies under development are focused on novel approaches to treat/improve Non-Alcoholic Steatohepatitis (NASH).Non-Alcoholic Steatohepatitis (NASH) Emerging Drugs ChaptersThis segment of the Non-Alcoholic Steatohepatitis (NASH) report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press Steatohepatitis (NASH) Emerging Drugs Lanifibranor: Inventiva PharmaLanifibranor, Inventiva's lead product candidate, is an orally-available small molecule that acts to induce antifibrotic, anti-inflammatory and beneficial vascular and metabolic changes in the body by activating all three peroxisome proliferator-activated receptor (PPAR) isoforms, which are well-characterized nuclear receptor proteins that regulate gene expression. Lanifibranor is a PPAR agonist that is designed to target all three PPAR isoforms in a moderately potent manner, with a well-balanced activation of PPARa and PPARd, and a partial activation of PPAR?. While other PPAR agonists target only one or two PPAR isoforms for activation. The FDA has granted Breakthrough Therapy and Fast Track designation to Lanifibranor for the treatment of NASH. Currently, the drug is in Phase III stage of its clinical trial for the treatment of Cirius TherapeuticsMSDC-0602K, a second-generation oral insulin sensitizer, is designed to selectively modulate the mitochondrial pyruvate carrier (MPC) while minimizing direct PPAR-gamma activation. The MPC mediates at the cellular level the effects of over nutrition, a major cause of Nonalcoholic fatty liver disease NAFLD/NASH and Type 2 diabetes. In preclinical studies, modulation of the MPC has been shown to improve insulin sensitivity, lipid metabolism, and inflammation. Currently the drug is in Phase III stage of Clinical trial for the treatment of Terns PharmaceuticalsTERN-501 is a THR-ß agonist with high metabolic stability, enhanced liver distribution and greater selectivity for THR-ß compared to other THR-ß agonists in development. Agonism of THR-ß increases fatty acid metabolism via mitochondrial oxidation and affects cholesterol synthesis and metabolism. As a result, THR-ß stimulation has the ability to reduce hepatic steatosis and improve serum lipid parameters including LDL cholesterol and triglycerides. In vivo NASH studies in a rodent model have demonstrated that low-doses of TERN-501 achieved complete resolution of steatosis and reductions in serum lipids, hepatic inflammation and fibrosis. TERN-501 has high liver distribution and is 23-fold more selective for THR-ß than for THR-ß activation in a cell free assay, thereby minimizing the risk of cardiotoxicity and other off-target effects associated with non-selective THR stimulation. Currently, the drug is in Phase II stage of its clinical trial for the treatment of 1801: HighTide BiopharmaThe company's lead drug candidate, HTD1801, is a first-in-class new molecular entity (ionic salt of two active moieties). It is a novel orally active ionic salt of berberine and ursodeoxycholic acid, substantially reduced liver fat while improving glycemic control and other cardiometabolic biomarkers in adults with nonalcoholic steatohepatitis (NASH) and type 2 diabetes (T2DM). Currently, it is in Phase II trials for the treatment of primary sclerosing cholangitis (PSC), and nonalcoholic steatohepatitis (NASH).LY3849891: Eli Lilly and CompanyLY3849891 is being developed by Eli Lilly and Company and is evaluated in participants with nonalcoholic fatty liver disease who have the patatin-like phospholipase domain-containing protein 3 (PNPLA3) I148M genotype. Currently, the drug is in Phase I stage of its clinical trial for the treatment of Steatohepatitis (NASH): Therapeutic AssessmentThis segment of the report provides insights about the different Non-Alcoholic Steatohepatitis (NASH) drugs segregated based on following parameters that define the scope of the report, such as:Major Players in Non-Alcoholic Steatohepatitis (NASH) There are approx. 80+ key companies which are developing the therapies for Non-Alcoholic Steatohepatitis (NASH). The companies which have their Non-Alcoholic Steatohepatitis (NASH) drug candidates in the most advanced stage, i.e. Phase III include, Cirius Therapeutics and Inventiva Pharma. Phases The report covers around 80+ products under different phases of clinical development, like: Late stage products (Phase III) Mid-stage products (Phase II) Early-stage product (Phase I) along with the details of: Pre-clinical and Discovery stage candidates Discontinued & Inactive candidates Route of AdministrationNon-Alcoholic Steatohepatitis (NASH) pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as: Oral Intravenous Subcutaneous Parenteral Topical Molecule Type Products have been categorized under various Molecule types, such as: Recombinant fusion proteins Small molecule Monoclonal antibody Peptide Polymer Gene therapy Product TypeDrugs have been categorized under various product types like Mono, Combination and Mono/ Development ActivitiesThe report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Non-Alcoholic Steatohepatitis (NASH) therapeutic drugs key players involved in developing key ActivitiesThe report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Non-Alcoholic Steatohepatitis (NASH) drugs. Key Questions Answered Current Treatment Scenario and Emerging Therapies: How many companies are developing Non-Alcoholic Steatohepatitis (NASH) drugs? How many Non-Alcoholic Steatohepatitis (NASH) drugs are developed by each company? How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Non-Alcoholic Steatohepatitis (NASH)? What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Non-Alcoholic Steatohepatitis (NASH) therapeutics? What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies? What are the clinical studies going on for Non-Alcoholic Steatohepatitis (NASH) and their status? What are the key designations that have been granted to the emerging drugs? Key Players Guangdong Raynovent Biotech Dr. Falk Pharma GmbH Enyo Pharma Viking Therapeutics Eli Lilly and Company Sagimet Biosciences Terns Sinew Pharma Madrigal Pharmaceuticals Hepion Pharmaceuticals Poxel SA Pfizer CytoDyn Altimmune Oramed, Ltd. PharmaKing Can-Fite Biopharma Cirius Therapeutics Key Products ZSP1601 ZED1227 EPY 651 VK2809 LY3849891 TVB-2640 TERN-501 SNP-630 Resmetirom Rencofilstat PXL065 PF-06865571 leronlimab Pemvidutide ORMD-0801 Oltipraz Namodenoson MSDC-0602K For more information about this clinical trials report visit About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. CONTACT: CONTACT: Laura Wood,Senior Press Manager press@ For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900Sign in to access your portfolio
India.com
30-04-2025
- Health
- India.com
Is Sedentary Lifestyle Linked To Fatty Liver Disease? Expert Advice On MASLD
In modern society, a sedentary lifestyle has become increasingly prevalent, characterized by prolonged periods of sitting, minimal physical activity, and high screen time. While the detrimental effects of this lifestyle on cardiovascular health and metabolic disorders like diabetes are well-established, its significant association with Metabolic dysfunction associated Steatotic Liver Disease (MASLD) is gaining increasing recognition within the medical community. Spokesperson Dr Srujan Kumar Dasyam, Consultant Medical Gastroenterologist, Hepatologist & Therapeutic Endoscopist, KIMS Hospital Hyderabad shares tips with us on how to improve liver health: MASLD is a condition where excess fat accumulates in the liver of individuals who consume little to no alcohol. It's a spectrum of conditions, ranging from simple steatosis (fatty liver) to Non-Alcoholic Steatohepatitis (NASH), which involves inflammation and liver cell damage, potentially leading to fibrosis, end stage liver disease called Cirhhosis and even liver cancer/Hepatocellular carcinoma. Several possible connections elucidate how a sedentary lifestyle contributes to the development and progression of MASLD. Firstly, reduced physical activity leads to decreased energy expenditure. This can result in a positive energy balance, where excess calories are stored as fat, including in the liver. As highlighted by Johns Hopkins Medicine, obesity and excess body weight, particularly abdominal fat, are significant risk factors for MASLD. Secondly, a sedentary lifestyle is often associated with metabolic dysfunction. According to the Mayo Clinic, insulin resistance, a condition where the body's cells become less responsive to insulin, is strongly linked to MASLD. Lack of physical activity can exacerbate insulin resistance, leading to increased fat storage in the liver. Furthermore, sedentary behavior can negatively impact lipid metabolism, resulting in elevated levels of triglycerides and low-density lipoprotein (LDL) cholesterol, further contributing to hepatic steatosis. Moreover, chronic low-grade inflammation, often seen in individuals with sedentary habits and obesity, may play a crucial role in the progression from simple fatty liver to NASH. Adipose tissue, especially visceral fat that accumulates with inactivity, releases pro-inflammatory cytokines, which can promote liver inflammation and damage. Advice for Patients to Improve Liver Health: For patients with or at risk of MASLD, adopting a more active lifestyle is paramount. Here are some practical steps: * Incorporate Regular Physical Activity: Aim for at least 150 minutes of moderate-intensity aerobic exercise per week, such as brisk walking, jogging, or cycling. Even shorter bursts of activity throughout the day can be beneficial. Johns Hopkins Medicine emphasizes that lifestyle changes, including weight loss through diet and exercise, are crucial for managing MASLD. * Reduce Sedentary Time: Break up long periods of sitting with short walks or standing breaks every 30 minutes. Consider incorporating standing desks or active workstations. * Adopt a Healthy Diet: Focus on a balanced diet rich in fruits, vegetables, whole grains, and lean proteins. Limit the intake of saturated and trans fats, processed foods, and sugary drinks. * Gradual Weight Loss: If overweight or obese, aim for gradual and sustainable weight loss, typically 1-2 pounds per week. Losing even 5-10% of body weight can significantly improve liver health. * Manage Underlying Conditions: Effectively manage conditions like type 2 diabetes, high blood pressure, and high cholesterol, as these are closely linked to NAFLD. By understanding the detrimental impact of a sedentary lifestyle on liver health and implementing these lifestyle adjustments, patients can take proactive steps towards improving their liver health and reducing the risk of NAFLD progression. Regular consultation with healthcare professionals is essential for personalized advice and monitoring.
